Steven Cohen’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$12.1M Buy
319,651
+290,453
+995% +$13.4M 0.01% 1238
2026
Q2
$1.4M Buy
+29,198
New +$1.25M ﹤0.01% 2614
2024
Q3
– Sell
-960,854
Closed -$128M – 2233
2024
Q2
$137M Buy
+960,854
New +$127M 0.36% 48
2023
Q3
– Sell
-134
Closed -$11.8K – 2755
2023
Q2
$10.8K Buy
+134
New +$10.9K ﹤0.01% 1907
2022
Q3
– Sell
-52,540
Closed -$2.93M – 1643
2022
Q2
$2.93M Sell
52,540
-1,117,060
-96% -$62M 0.01% 848
2022
Q1
$64.9M Buy
+1,169,600
New +$60M 0.26% 103
2020
Q1
– Sell
-117,240
Closed -$3.39M – 991
2019
Q4
$3.39M Buy
+117,240
New +$3.25M 0.02% 550
2019
Q2
– Sell
-1,662,208
Closed -$43.5M – 1477
2019
Q1
$43.5M Sell
1,662,208
-120,204
-7% -$2.95M 0.2% 130
2018
Q4
$41.1M Buy
+1,782,412
New +$39.6M 0.2% 140
2018
Q1
– Sell
-591,726
Closed -$15.9M – 1065
2017
Q4
$15.9M Buy
591,726
+292,926
+98% +$7.45M 0.07% 351
2017
Q3
$7.19M Buy
+298,800
New +$6.75M 0.03% 474
2015
Q1
– Sell
-963,400
Closed -$20.4M – 757
2014
Q4
$20.4M Buy
+963,400
New +$21.5M 0.14% 212

Other funds holding NVO

Steven Cohen's NVO Position: Q3 2026 in Review

Steven Cohen increased its Novo Nordisk (NVO) stake by 995% in Q3 2026, buying an estimated $13.4M and bringing the position to 319,651 shares worth $12.1M. The position accounts for 0.01% of the portfolio, ranked #1238.

Steven Cohen first reported a position in NVO in Q4 2014 and has held it in 12 quarters since. The position peaked at $137M in Q2 2024. 1,224 funds tracked by Wall St. Rank hold NVO as of Q3 2026.

  • Steven Cohen held 319,651 shares of Novo Nordisk worth $12.1M as of Q3 2026.
  • Steven Cohen bought 290,453 Novo Nordisk shares in Q3 2026, an estimated $13.4M.
  • Novo Nordisk made up 0.01% of Steven Cohen's portfolio in Q3 2026, its #1238 holding.
  • Steven Cohen first reported a position in Novo Nordisk in Q4 2014 and has held it in 12 quarters since.
  • Steven Cohen's Novo Nordisk position peaked at $137M in Q2 2024.
  • 1,224 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2026.

Based on Point72 Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.